Biocartis employs approximately 300 people and is headquartered in Mechelen, Belgium. Biocartis develops novel diagnostic technology platforms. The company produces molecular platforms for sample preparation of nucleic acids, amplification, detection, and generation. The company's proprietary MDx Idylla platform is a fully automated, real time system which offers highly-reliable molecular information from any biological sample in virtually any setting. Idylla addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.